Expert Advice 20 Mar 2023 Nine tips to succeed in pharma-biotech partnerships The question of whether to partner with another company is critical to the long-term development of a biotech. Nonetheless, it can be easy for a small company to underestimate the resources it needs to put into a successful collaboration. Here, we’ll go over some expert advice on what to do and what not to do […] March 20, 2023 - 9 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jul 2019 Belgian Biotech Raises €35M to Develop Eco-Friendly Pesticides The Belgium-based company AgroSavfe has raised a Series C round of €35M to develop an environmentally friendly crop pesticide inspired by llama antibodies. AgroSavfe will use the funds to develop and manufacture its lead protein fungicide on a commercial scale. The company aims to get approval from the US Environmental Protection Agency and launch the […] July 30, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 4 Sep 2018 The EMA Approves the First Nanobody from Ablynx Update: The EMA has officially approved Cablivi for the treatment of adults with acquired thrombotic thrombocytopenic purpura, following its earlier recommendation in June. The drug has also been accepted for priority review by the US FDA, with a decision due on 6 Feb 2019. Published 29.6.18 Just a few months after Sanofi acquired Ablynx in a multi-billion euro […] September 4, 2018 - 2 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Interview 30 May 2018 How to Close a €3.9B Acquisition Deal for Your Biotech Company Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […] May 30, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B Sanofi will acquire Ablynx and get its hands on the biotech’s exciting Nanobody technology just months after the biotech joined Europe’s billion-euro biotech club. Despite rejecting the advances of Novo Nordisk earlier this month, a decision that led to a 60% jump in Ablynx’s stock, the biotech has voted unanimously in favor of being acquired Sanofi. Sanofi has […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Dec 2017 Smile! Here are the 12 Biggest Biotech Clinical Successes of 2017 Now that we’ve got the bad news out of the way, we’re here to spread some Christmas cheer with the biggest clinical successes in biotech over the past 12 months. It’s unlikely that one whole year will ever pass without a single hiccup, especially in a field as complex as biotech. For that reason, we […] December 18, 2017 - 9 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 11 Dec 2017 Edwin Moses on how Ablynx has made it to the top of European biotech Ablynx CEO Edwin Moses discusses the technology and strategy that has led its company to join the ranks of the biggest European biotechs. Ablynx, based in Belgium, has just recently joined the European billion-euro biotech club with a market cap of €1.45Bn. With positive Phase III results for its lead compound and a $230M (€195M) […] December 11, 2017 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Dec 2017 Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017 Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the top things that happened this year. First up, the best biotech companies of 2017! After the doozy of 2016 for biotech and pharma, things could only get better this year — and the European industry […] December 5, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2017 Ablynx Launches $175M IPO on Wall Street After Phase III Success Fresh from announcing positive Phase III results, Ablynx has wasted no time in filing a $175M (€148M) IPO to continue developing its nanobodies technology. On Monday, the Belgian biotech shared the news that its nanobody, caplacizumab, received encouraging results for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood disorder. This news boosted the company’s […] October 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Oct 2017 Belgian Biotech Breaks New Ground in Fight Against Life-Threatening Blood Disorder Ablynx has triumphed where others have fallen by receiving positive Phase III results for the treatment of a dangerous blood disorder with caplacizumab. Ablynx develops nanobodies, molecules with the specificity of antibodies but much smaller in size. Its product, caplacizumab, has received encouraging results for the treatment of the life-threatening autoimmune blood disorder, acquired thrombotic thrombocytopenic purpura (aTTP), which […] October 2, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2017 Sanofi Offers up to €2.4Bn to Belgian Biotech to Develop Nanobodies Ablynx and Sanofi have entered a research collaboration and exclusive licensing agreement for up to eight nanobody candidates for immune and inflammatory disease. Ablynx, based in Belgium, develops nanobodies, single-domain antibodies inspired on those of camels and llamas that have the advantage of being much smaller than standard antibodies. This technology has caught the attention of Sanofi, […] July 20, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email